Astria Therapeutics' Final Phase 1b/2 Trial Results For Hereditary Angioedema Treatment Show Strong Efficacy
MT Newswires Live
Nov 07, 2025
Astria Therapeutics (ATXS) said Thursday the final results of its phase 1b/2 clinical trial evaluating navenibart in hereditary angioedema patients showed strong efficacy and a favorable safety and tolerability profile.
Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling.
Conducted across 20 sites in six countries, the trial results showed a significant attack rate reduction, supporting both dosing regimens of every three months and every six months, the company said.
The phase 3 trial is progressing, with topline results expected in early 2027, Astria said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.